Femasys (FEMY) announced that it received the Medicines and Healthcare products Regulatory Agency, MHRA, approval for its FemBloc Permanent Birth Control, which signifies the product has met the required standards for safety, quality, and effectiveness in the United Kingdom, UK. This marks an important milestone in the Company’s efforts to expand the availability of this non-surgical permanent birth control option to women in Europe.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY: